CVRx (NASDAQ:CVRX - Get Free Report)'s stock had its "sell (d-)" rating restated by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.
Several other brokerages have also issued reports on CVRX. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 target price on shares of CVRx in a research report on Tuesday, August 5th. William Blair raised CVRx to a "strong-buy" rating in a research report on Monday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, CVRx currently has an average rating of "Moderate Buy" and a consensus price target of $14.00.
Get Our Latest Analysis on CVRx
CVRx Stock Up 4.4%
NASDAQ CVRX traded up $0.38 on Wednesday, reaching $9.11. The company had a trading volume of 237,423 shares, compared to its average volume of 201,876. The stock has a market capitalization of $238.24 million, a P/E ratio of -4.34 and a beta of 1.26. The company's fifty day moving average is $7.63 and its 200 day moving average is $7.46. CVRx has a 52-week low of $4.30 and a 52-week high of $18.55. The company has a quick ratio of 10.78, a current ratio of 11.99 and a debt-to-equity ratio of 0.85.
CVRx (NASDAQ:CVRX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05). The company had revenue of $13.59 million during the quarter, compared to analysts' expectations of $13.22 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that CVRx will post -1.91 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Cresset Asset Management LLC boosted its stake in CVRx by 3.5% in the 2nd quarter. Cresset Asset Management LLC now owns 53,542 shares of the company's stock worth $315,000 after purchasing an additional 1,823 shares during the period. Rhumbline Advisers boosted its position in shares of CVRx by 13.0% during the 1st quarter. Rhumbline Advisers now owns 19,018 shares of the company's stock valued at $233,000 after acquiring an additional 2,192 shares during the last quarter. Larson Financial Group LLC bought a new stake in shares of CVRx during the 1st quarter valued at about $28,000. Deutsche Bank AG boosted its position in shares of CVRx by 41.5% during the 1st quarter. Deutsche Bank AG now owns 10,390 shares of the company's stock valued at $127,000 after acquiring an additional 3,048 shares during the last quarter. Finally, Tradewinds LLC. boosted its position in shares of CVRx by 5.8% during the 1st quarter. Tradewinds LLC. now owns 58,011 shares of the company's stock valued at $709,000 after acquiring an additional 3,175 shares during the last quarter. Institutional investors own 75.27% of the company's stock.
About CVRx
(
Get Free Report)
CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CVRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVRx wasn't on the list.
While CVRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.